Delayed engraftment is a significant limitation of umbilical cord blood (UCB) transplantation due to low stem cell numbers. Inhibition of dipeptidyl peptidase (DPP)-4 enhanced engraftment in murine transplants. We evaluated the feasibility of systemic DPP-4 inhibition using sitagliptin to enhance engraftment of single-unit UCB grafts in adults with hematological malignancies. Twenty-four patients (21–58 years) received myeloablative conditioning, followed by sitagliptin 600 mg orally days −1 to +2, and single UCB grafts day 0. Seventeen receiving red cell-depleted (RCD) grafts, matched at 4 (n=10) or 5 (n=7) of 6 human leucocyte antigen (HLA) loci with median nucleated cell dose 3.6 (2.5–5.2)×107/kg, engrafted at median of 21 (range, 13–50) days with cumulative incidence of 94% (95% confidence interval, 84%–100%) at 50 days. Plasma DDP-4 activity was reduced to 23%±7% within 2 h. Area under DPP-4 activity-time curve (AUCA) correlated with engraftment; 9 of 11 with AUCA <6,000 activity·h engrafted within ≤21 days, while all 6 with higher AUCA engrafted later (P=0.002). Seven patients receiving red cell replete grafts had 10-fold lower colony forming units after thawing compared with RCD grafts, with poor engraftment. Systemic DPP-4 inhibition was well tolerated and may enhance engraftment. Optimizing sitagliptin dosing to achieve more sustained DPP-4 inhibition may further improve outcome.
BarkerJN, WeisdorfDJ, DeForTE, BlazarBR, McGlavePB, MillerJS, VerfaillieCM, WagnerJE. 2005. Transplantation of 2 partially HLA-matched umbilical cord blood units to enhance engraftment in adults with hematologic malignancy. Blood, 105:1343–1347.
3.
RochaV, CrottaA, RuggeriA, PurtillD, BoudjedirK, HerrAL, IonescuI, GluckmanE. 2010. Double cord blood transplantation: extending the use of unrelated umbilical cord blood cells for patients with hematological diseases. Best Pract Res Clin Haematol, 23:223–229.
4.
DelaneyC, HeimfeldS, Brashem-SteinC, VoorhiesH, MangerRL, BernsteinID. 2010. Notch-mediated expansion of human cord blood progenitor cells capable of rapid myeloid reconstitution. Nat Med, 16:232–236.
5.
BautistaG, CabreraJR, RegidorC, ForesR, Garcia-MarcoJA, OjedaE, SanjuanI, RuizE, KrsnikIet al.2009. Cord blood transplants supported by co-infusion of mobilized hematopoietic stem cells from a third-party donor. Bone Marrow Transplant, 43:365–373.
6.
LiuH, RichES, GodleyL, OdenikeO, JosephL, MarinoS, KlineJ, NguyenV, CunninghamJet al.2011. Reduced-intensity conditioning with combined haploidentical and cord blood transplantation results in rapid engraftment, low GVHD, and durable remissions. Blood, 118:6438–6445.
7.
PeledA, PetitI, KolletO, MagidM, PonomaryovT, BykT, NaglerA, Ben-HurH, ManyAet al.1999. Dependence of human stem cell engraftment and repopulation of NOD/SCID mice on CXCR4. Science, 283:845–848.
8.
BroxmeyerHE, CooperS, KohliL, HangocG, LeeY, MantelC, ClappDW, KimCH. 2003. Transgenic expression of stromal cell-derived factor-1/CXC chemokine ligand 12 enhances myeloid progenitor cell survival/antiapoptosis in vitro in response to growth factor withdrawal and enhances myelopoiesis in vivo. J Immunol, 170:421–429.
9.
ChristophersonKW2nd, HangocG, BroxmeyerHE. 2002. Cell surface peptidase CD26/dipeptidylpeptidase IV regulates CXCL12/stromal cell-derived factor-1 alpha-mediated chemotaxis of human cord blood CD34+ progenitor cells. J Immunol, 169:7000–7008.
10.
ChristophersonKW2nd, HangocG, MantelCR, BroxmeyerHE. 2004. Modulation of hematopoietic stem cell homing and engraftment by CD26. Science, 305:1000–1003.
11.
DurinxC, LambeirAM, BosmansE, FalmagneJB, BerghmansR, HaemersA, ScharpeS, De MeesterI. 2000. Molecular characterization of dipeptidyl peptidase activity in serum: soluble CD26/dipeptidyl peptidase IV is responsible for the release of X-Pro dipeptides. Eur J Biochem, 267:5608–5613.
12.
MentleinR. 1999. Dipeptidyl-peptidase IV (CD26)—role in the inactivation of regulatory peptides. Regul Pept, 85:9–24.
13.
CampbellTB, HangocG, LiuY, PollokK, BroxmeyerHE. 2007. Inhibition of CD26 in human cord blood CD34+ cells enhances their engraftment of nonobese diabetic/severe combined immunodeficiency mice. Stem Cells Dev, 16:347–354.
14.
ChristophersonKW2nd, PaganessiLA, NapierS, PorechaNK. 2007. CD26 inhibition on CD34+ or lineage- human umbilical cord blood donor hematopoietic stem cells/hematopoietic progenitor cells improves long-term engraftment into NOD/SCID/Beta2null immunodeficient mice. Stem Cells Dev, 16:355–360.
15.
KawaiT, ChoiU, LiuPC, Whiting-TheobaldNL, LintonGF, MalechHL. 2007. Diprotin A infusion into nonobese diabetic/severe combined immunodeficiency mice markedly enhances engraftment of human mobilized CD34+ peripheral blood cells. Stem Cells Dev, 16:361–370.
16.
BroxmeyerHE, HangocG, CooperS, CampbellT, ItoS, MantelC. 2007. AMD3100 and CD26 modulate mobilization, engraftment, and survival of hematopoietic stem and progenitor cells mediated by the SDF-1/CXCL12-CXCR4 axis. Ann N Y Acad Sci, 1106:1–19.
17.
CampbellTB, BroxmeyerHE. 2008. CD26 inhibition and hematopoiesis: a novel approach to enhance transplantation. Front Biosci, 13:1795–1805.
RubinsteinP, DobrilaL, RosenfieldRE, AdamsonJW, MigliaccioG, MigliaccioAR, TaylorPE, StevensCE. 1995. Processing and cryopreservation of placental/umbilical cord blood for unrelated bone marrow reconstitution. Proc Natl Acad Sci U S A, 92:10119–10122.
20.
CutlerC, KimHT, HochbergE, HoV, AlyeaE, LeeSJ, FisherDC, MiklosD, LevinJet al.2004. Sirolimus and tacrolimus without methotrexate as graft-versus-host disease prophylaxis after matched related donor peripheral blood stem cell transplantation. Biol Blood Marrow Transplant, 10:328–336.
21.
BergmanAJ, StevensC, ZhouY, YiB, LaethemM, De SmetM, SnyderK, HilliardD, TanakaWet al.2006. Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: a double-blind, randomized, placebo-controlled study in healthy male volunteers. Clin Ther, 28:55–72.
22.
NakamuraY, LeppertM, O'ConnellP, WolffR, HolmT, CulverM, MartinC, FujimotoE, HoffMet al.1987. Variable number of tandem repeat (VNTR) markers for human gene mapping. Science, 235:1616–1622.
23.
AtkinsonK, HorowitzMM, GaleRP, LeeMB, RimmAA, BortinMM. 1989. Consensus among bone marrow transplanters for diagnosis, grading and treatment of chronic graft-versus-host disease. Committee of the International Bone Marrow Transplant Registry. Bone Marrow Transplant, 4:247–254.
24.
PrzepiorkaD, WeisdorfD, MartinP, KlingemannHG, BeattyP, HowsJ, ThomasED. 1995. 1994 consensus conference on acute GVHD grading. Bone Marrow Transplant, 15:825–828.
25.
KaplanEL, MeierP. 1958. Nonparametric estimation from incomplete observations. J Am Stat Assoc, 53:457–481.
26.
BarkerJN, ScaradavouA, StevensCE. 2010. Combined effect of total nucleated cell dose and HLA match on transplantation outcome in 1061 cord blood recipients with hematologic malignancies. Blood, 115:1843–1849.
27.
SanzJ, BoludaJC, MartinC, GonzalezM, FerraC, SerranoD, de HerediaCD, BarrenetxeaC, MartinezAMet al.2012. Single-unit umbilical cord blood transplantation from unrelated donors in patients with hematological malignancy using busulfan, thiotepa, fludarabine and ATG as myeloablative conditioning regimen. Bone Marrow Transplant, 47:1287–1293.
28.
PageKM, ZhangL, MendizabalA, WeaseS, CarterS, GentryT, BalberAE, KurtzbergJ. 2011. Total colony-forming units are a strong, independent predictor of neutrophil and platelet engraftment after unrelated umbilical cord blood transplantation: a single-center analysis of 435 cord blood transplants. Biol Blood Marrow Transplant, 17:1362–1374.
29.
GluckmanE, RochaV, Boyer-ChammardA, LocatelliF, ArceseW, PasquiniR, OrtegaJ, SouilletG, FerreiraEet al.1997. Outcome of cord-blood transplantation from related and unrelated donors. Eurocord Transplant Group and the European Blood and Marrow Transplantation Group. N Engl J Med, 337:373–381.
30.
RubinsteinP, CarrierC, ScaradavouA, KurtzbergJ, AdamsonJ, MigliaccioAR, BerkowitzRL, CabbadM, DobrilaNLet al.1998. Outcomes among 562 recipients of placental-blood transplants from unrelated donors. N Engl J Med, 339:1565–1577.
31.
WagnerJE, BarkerJN, DeForTE, BakerKS, BlazarBR, EideC, GoldmanA, KerseyJ, KrivitWet al.2002. Transplantation of unrelated donor umbilical cord blood in 102 patients with malignant and nonmalignant diseases: influence of CD34 cell dose and HLA disparity on treatment-related mortality and survival. Blood, 100:1611–1618.
32.
LaughlinMJ, BarkerJ, BambachB, KocON, RizzieriDA, WagnerJE, GersonSL, LazarusHM, CairoMet al.2001. Hematopoietic engraftment and survival in adult recipients of umbilical-cord blood from unrelated donors. N Engl J Med, 344:1815–1822.
33.
BarkerJN. 2007. Who should get cord blood transplants?Biol Blood Marrow Transplant, 13:78–82.
34.
RosenstockJ, ZinmanB. 2007. Dipeptidyl peptidase-4 inhibitors and the management of type 2 diabetes mellitus. Curr Opin Endocrinol Diabetes Obes, 14:98–107.
35.
RochaV, LabopinM, SanzG, ArceseW, SchwerdtfegerR, BosiA, JacobsenN, RuutuT, de LimaMet al.2004. Transplants of umbilical-cord blood or bone marrow from unrelated donors in adults with acute leukemia. N Engl J Med, 351:2276–2285.
36.
LaughlinMJ, EapenM, RubinsteinP, WagnerJE, ZhangMJ, ChamplinRE, StevensC, BarkerJN, GaleRPet al.2004. Outcomes after transplantation of cord blood or bone marrow from unrelated donors in adults with leukemia. N Engl J Med, 351:2265–2275.
37.
TakahashiS, OoiJ, TomonariA, KonumaT, TsukadaN, Oiwa-MonnaM, FukunoK, UchiyamaM, TakasugiKet al.2007. Comparative single-institute analysis of cord blood transplantation from unrelated donors with bone marrow or peripheral blood stem-cell transplants from related donors in adult patients with hematologic malignancies after myeloablative conditioning regimen. Blood, 109:1322–1330.
38.
EapenM, RochaV, SanzG, ScaradavouA, ZhangMJ, ArceseW, SirventA, ChamplinRE, ChaoNet al.Center for International, R Marrow Transplant, E Acute Leukemia Working Party and C National Cord Blood Program of the New York Blood. 2010. Effect of graft source on unrelated donor haemopoietic stem-cell transplantation in adults with acute leukaemia: a retrospective analysis. Lancet Oncol, 11:653–660.
39.
BrunsteinCG, GutmanJA, WeisdorfDJ, WoolfreyAE, DeforTE, GooleyTA, VernerisMR, AppelbaumFR, WagnerJE, DelaneyC. 2010. Allogeneic hematopoietic cell transplantation for hematologic malignancy: relative risks and benefits of double umbilical cord blood. Blood, 116:4693–4699.
40.
ChowR, NademaneeA, RosenthalJ, KaranesC, JaingTH, GrahamML, TsukaharaE, WangB, GjertsonDet al.2007. Analysis of hematopoietic cell transplants using plasma-depleted cord blood products that are not red blood cell reduced. Biol Blood Marrow Transplant, 13:1346–1357.
41.
RochaV, BroxmeyerHE. 2010. New approaches for improving engraftment after cord blood transplantation. Biol Blood Marrow Transplant, 16:S126–S132.
42.
Kindwall-KellerTL, HegerfeldtY, MeyersonHJ, MargeviciusS, FuP, van HeeckerenW, LazarusHM, CooperBW, GersonSLet al.2012. Prospective study of one- vs two-unit umbilical cord blood transplantation following reduced intensity conditioning in adults with hematological malignancies. Bone Marrow Transplant, 47:924–933.
43.
FrassoniF, GualandiF, PodestaM, RaiolaAM, IbaticiA, PiaggioG, SessaregoM, SessaregoN, GobbiMet al.2008. Direct intrabone transplant of unrelated cord-blood cells in acute leukaemia: a phase I/II study. Lancet Oncol, 9:831–839.
44.
RobinsonSN, SimmonsPJ, ThomasMW, BrouardN, JavniJA, TrilokS, ShimJS, YangH, SteinerDet al.2012. Ex vivo fucosylation improves human cord blood engraftment in NOD-SCID IL-2Rgamma(null) mice. Exp Hematol, 40:445–456.
